Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials

BACKGROUND: Doxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, we comprehensively compared the efficacy and tole...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Bi-Cheng, Kuang, Bo-Hua, Xiao, Bo-Ya, Lin, Guo-He
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648074/
https://www.ncbi.nlm.nih.gov/pubmed/34881180
http://dx.doi.org/10.3389/fonc.2021.762288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648074/
https://www.ncbi.nlm.nih.gov/pubmed/34881180
http://dx.doi.org/10.3389/fonc.2021.762288

Ejemplares similares